Paeds Vivas · neurology-neurodisability-and-neuromuscular
Neurodegenerative and leukodystrophy disorders — branching viva
Branching viva on neurodegenerative and leukodystrophy disorders: reading the contrasted brain MRI to name the mechanism group, recognising the transplant emergency of cerebral X-linked adrenoleukodystrophy, deploying a magnetic-resonance-imaging-led tiered workup, matching disease-modifying therapy to the named disorder, and understanding that the treatable leukodystrophies are treated before symptoms begin through newborn screening.
On this page & tools
Target exams
Opening branch — the boy with the parieto-occipital lesion
A previously well seven-year-old presents with two months of school decline, difficulty following the ball at sport, and intermittent vomiting, with an unenhanced brain MRI showing symmetric parieto-occipital white-matter change. The candidate must first recognise this as a likely cerebral X-linked adrenoleukodystrophy and name the mechanism-based classification - lysosomal and dysmyelinating, peroxisomal and inflammatory, hypomyelinating, astrocytopathic and interferonopathic - placing this disorder in the peroxisomal and inflammatory group driven by very-long-chain fatty acid accumulation and CD8 T-cell-mediated inflammation. [1] [2]
The examiner probes the management decision. The candidate states that the single addition that settles the transplant question is gadolinium contrast, because the enhancing leading edge of the inflammatory phase confirms active cerebral disease and is missed on the unenhanced scan, and that the Loes score alongside the neurological examination stages the disease. The teaching point is that allogeneic haematopoietic stem cell transplant halts the inflammation only when the burden is still low and the examination preserved, so the case is a transplant-pace emergency referred the same day. [2]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Parikh S, Bernard G, Leventer RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab, 2015.PMID 25655951
- [2]Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology, 2022.PMID 36175155
- [3]Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis, 2021.PMID 33373467
- [4]Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial and an extension study. Lancet, 2016.PMID 27289174
- [5]van Voorst RJ, Schoenmakers DH, Bonkowsky JL, et al. Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter. Neurology, 2025.PMID 41232062